The recipient of multiple international design awards, Atomo creates devices that address the problems commonly associated with standard multi-component rapid diagnostic test kits.

Atomo’s all-in-one RDT platforms put the end user first and make it easy to test and screen for a range of infectious diseases and chronic conditions.

 

Their unmatched usability has won the respect of frontline healthcare providers worldwide, and has made Atomo the OEM partner of choice for diagnostic manufacturers looking to transform their RDT offerings.

Device Portfolio >

Award-winning Australian innovation

Atomo Diagnostics is a specialist medical device design innovator and original equipment manufacturing (OEM) company whose unique proprietary technologies support usability, accuracy, and safety. Headquartered in Sydney, Australia, Atomo has emerged as a global leader in the development of point of care devices for rapid diagnostic testing (RDT).

 

Atomo’s operations are ISO 9001 and ISO 13485 certified for the design, development, and manufacture of in vitro diagnostic medical devices.

Designed for simplicity

Atomo’s device solutions address challenges associated with in-field deployment of standard RDT kits.  The focus on usability and simplicity in design means Atomo’s integrated RDT platforms are easy to learn and teach, and suitable for use in a variety of real world settings, including doctor’s offices, pharmacies, point of care settings, community clinics, and the home.

 

AtomoRapid™ RDT platforms are customisable to suit a variety of blood-based lateral flow test assays and are appropriate for a range of applications, including screening for chronic conditions and detection of infectious diseases.

Atomo-Diagnostics-Award-Logo-150x150

Atomo News

An article by Biotech Dispatch on our expanded partnership with Access Bio to launch a rapid COVID-19 antigen test in Australia, New Zealand and India.   Read the full article >    ...

Our MD, John Kelly sat down with Ausbiz to discuss our rapid antigen test deal with Access Bio which will enable screening for COVID-19 acute infection and exposure at the same time.   Watch the Video    ...